Cullinan Therapeutics, Inc. (CGEM) News
Track canonical SquawkNews coverage tagged to CGEM, Cullinan Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 13 indexed stories across 8 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Cullinan Therapeutics Starts FDA NDA for Zipalertinib Combo
Cullinan Therapeutics has initiated a New Drug Application via the FDA Real-Time Oncology Review program for zipalertinib plus platinum chemotherapy in first-line EGFR exon 20 insertion NSCLC. This submission is based on
EQUITY | Oct 01, 2026, 11:32 PM UTC
L
Weekly Recap: CLN—978 Dec 2026 data release and HC Wainwright $35 target
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) said it will report December 2026 single— and multi—dose CLN—978 data for refractory SLE, hard—to—treat RA and refractory Sjögren’s—with the multi—dose readout flagged as a Q4 20
NEWS | Sep 28, 2026, 11:08 AM UTC
L
Cullinan Therapeutics Price Target Raised to $35.00/Share From $30.00 by HC Wainwright & Co.
Ratings actions from Benzinga: GMT) Cullinan Therapeutics Is Maintained at Buy by HC Wainwright & Co.Ratings actions from Benzinga
NEWS | Sep 25, 2026, 11:58 AM UTC
L
Cullinan Therapeutics Price Target Maintained With a $40.00/Share by BTIG
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 09:59 AM UTC
L
CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger
Cullinan Therapeutics (CGEM) shares tumbled as much as 12% on Thursday after the company outlined fourth-quarter pipeline updates that pushed rheumatoid arthritis data later than previously signaled.The decline reflected
EQUITY | Sep 24, 2026, 07:09 PM UTC
L
Cullinan Therapeutics outlines Q4 2026 data milestones for CLN-978, velinotamig and CLN-049
Cullinan Therapeutics announced planned Q4 2026 data readouts for CLN-978, velinotamig and CLN-049.Key Highlights:Original SEC Filing: Cullinan Therapeutics, Inc. [ CGEM ] - 8-K - Sep. 24, 2026This is an AI-powered summa
REGULATION | Sep 24, 2026, 11:44 AM UTC
L
Cullinan Therapeutics, Inc. (CGEM) Sets Q4 Data Milestones in Autoimmune and Oncology
Cullinan Therapeutics will present multi-dose regimen data for CLN-978 in SLE, RA and Sjögren’s in December, velinotamig SLE data at ACR in November, and updated CLN-049 AML Phase 1 data in December, with plans to initia
NEWS | Sep 24, 2026, 11:01 AM UTC
L
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in NovemberCLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren’s disease in DecemberCLN-049 (FLT3 TCE) updated data from the Pha
NEWS | Sep 24, 2026, 11:01 AM UTC
L
CGEM - Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
CGEM - Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
NEWS | Sep 24, 2026, 11:00 AM UTC
L
CGEM - Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
CGEM - Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
NEWS | Sep 21, 2026, 04:00 PM UTC
L
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial evaluating zipalertinib plus chemotherapy versus chemotherapy
NEWS | Sep 13, 2026, 11:15 PM UTC
H
Catalyst Watch: FOMC blockbuster, Salesforce event, and 24-hour trading talk
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week.Monday - September 14Tuesday - September
CENTRAL_BANK | Sep 11, 2026, 07:01 PM UTC
L
CGEM - Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
CGEM - Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 06, 2026, 11:00 AM UTC